Junhao Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junhao Xiong has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bing Zhang
Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Department of Cardiovascular Surgery, Shanghai Chest Hospital, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute of Developmental and Regenerative Medicine, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2 shared publications - Dan Zhu
Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Department of Cardiovascular Surgery, Shanghai Chest Hospital, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute of Developmental and Regenerative Medicine, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication Juntao Lin
Shanghai Chest Hospital
1 shared publicationKang Cheng
Shanghai Chest Hospital
1 shared publicationLianpin Wu
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
1 shared publication- Ruogu Li
Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy
Background: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long‐term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. Methods: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno‐associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail‐cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension‐associated comorbidities were examined through histological analysis and ELISA. A modified N‐acetylgalactosamine‐conjugated small interfering RNA targeting human hepatic AGT (GalNAc‐siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. Results: The dual adeno‐associated virus‐induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc‐siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc‐siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio‐ and renoprotective effects. Moreover, combining GalNAc‐siAGT with the renin‐angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. Conclusions: Our study validated the antihypertensive therapeutic effect of GalNAc‐siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy
Background: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long‐term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. Methods: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno‐associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail‐cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension‐associated comorbidities were examined through histological analysis and ELISA. A modified N‐acetylgalactosamine‐conjugated small interfering RNA targeting human hepatic AGT (GalNAc‐siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. Results: The dual adeno‐associated virus‐induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc‐siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc‐siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio‐ and renoprotective effects. Moreover, combining GalNAc‐siAGT with the renin‐angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. Conclusions: Our study validated the antihypertensive therapeutic effect of GalNAc‐siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.
- 31 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (13) , e1059-e1060
Response by Xiong and Zhang to Letter Regarding Article, “An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure”
- 31 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (13) , e1059-e1060
Response by Xiong and Zhang to Letter Regarding Article, “An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure”